231 related articles for article (PubMed ID: 35993275)
1. The A to I editing landscape in melanoma and its relation to clinical outcome.
Amweg A; Tusup M; Cheng P; Picardi E; Dummer R; Levesque MP; French LE; Guenova E; Läuchli S; Kundig T; Mellett M; Pascolo S
RNA Biol; 2022 Jan; 19(1):996-1006. PubMed ID: 35993275
[TBL] [Abstract][Full Text] [Related]
2. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma.
Tusup M; Cheng PF; Picardi E; Raziunaite A; Dummer R; Levesque MP; French LE; Guenova E; Kundig TM; Pascolo S
Noncoding RNA; 2021 Jan; 7(1):. PubMed ID: 33445472
[TBL] [Abstract][Full Text] [Related]
4. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Ascierto PA; Schadendorf D; Berking C; Agarwala SS; van Herpen CM; Queirolo P; Blank CU; Hauschild A; Beck JT; St-Pierre A; Niazi F; Wandel S; Peters M; Zubel A; Dummer R
Lancet Oncol; 2013 Mar; 14(3):249-56. PubMed ID: 23414587
[TBL] [Abstract][Full Text] [Related]
5. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
6. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis.
Shoshan E; Mobley AK; Braeuer RR; Kamiya T; Huang L; Vasquez ME; Salameh A; Lee HJ; Kim SJ; Ivan C; Velazquez-Torres G; Nip KM; Zhu K; Brooks D; Jones SJ; Birol I; Mosqueda M; Wen YY; Eterovic AK; Sood AK; Hwu P; Gershenwald JE; Robertson AG; Calin GA; Markel G; Fidler IJ; Bar-Eli M
Nat Cell Biol; 2015 Mar; 17(3):311-21. PubMed ID: 25686251
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.
Delyon J; Lebbe C; Dumaz N
Curr Opin Oncol; 2020 Mar; 32(2):79-84. PubMed ID: 31833955
[TBL] [Abstract][Full Text] [Related]
10. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
Sperduto PW; Jiang W; Brown PD; Braunstein S; Sneed P; Wattson DA; Shih HA; Bangdiwala A; Shanley R; Lockney NA; Beal K; Lou E; Amatruda T; Sperduto WA; Kirkpatrick JP; Yeh N; Gaspar LE; Molitoris JK; Masucci L; Roberge D; Yu J; Chiang V; Mehta M
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1069-1077. PubMed ID: 28721890
[TBL] [Abstract][Full Text] [Related]
12. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
13. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
14. The role of MEK inhibitors in the treatment of metastatic melanoma.
Grimaldi AM; Simeone E; Ascierto PA
Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
Kiniwa Y; Okuyama R
Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
[TBL] [Abstract][Full Text] [Related]
16. Association of activated c-Met with NRAS-mutated human melanomas.
Chattopadhyay C; Ellerhorst JA; Ekmekcioglu S; Greene VR; Davies MA; Grimm EA
Int J Cancer; 2012 Jul; 131(2):E56-65. PubMed ID: 22020736
[TBL] [Abstract][Full Text] [Related]
17. In cancer, A-to-I RNA editing can be the driver, the passenger, or the mechanic.
Ganem NS; Ben-Asher N; Lamm AT
Drug Resist Updat; 2017 May; 32():16-22. PubMed ID: 29145975
[TBL] [Abstract][Full Text] [Related]
18. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.
Montagnani V; Maresca L; Apollo A; Pepe S; Carr RM; Fernandez-Zapico ME; Stecca B
J Biol Chem; 2020 Nov; 295(47):16058-16071. PubMed ID: 32938713
[TBL] [Abstract][Full Text] [Related]
19. Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.
Conrad WH; Swift RD; Biechele TL; Kulikauskas RM; Moon RT; Chien AJ
Cell Cycle; 2012 Oct; 11(20):3724-30. PubMed ID: 22895053
[TBL] [Abstract][Full Text] [Related]
20. Principles of Targeted Therapy for Melanoma.
Sun J; Carr MJ; Khushalani NI
Surg Clin North Am; 2020 Feb; 100(1):175-188. PubMed ID: 31753111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
